BiotechTube
Volumina Medical

Volumina Medical

Lausanne, Switzerland· Est.
volumina-medical.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Volumina Medical is a private, preclinical-stage biotech focused on addressing soft tissue volume loss through its proprietary AdiPearl™ biomaterial platform. The technology aims to enable minimally invasive, durable reconstruction of 3D tissue volumes in a single injection, targeting high unmet needs in reconstructive surgery and aesthetic medicine. The company has secured non-dilutive grant support and Series pre-A funding, building on strong academic roots and an experienced leadership team to advance its regenerative medicine solutions.

Reconstructive SurgeryPlastic SurgeryAesthetic Medicine

Technology Platform

Injectable cryogel-based biomaterial scaffold (AdiPearl™) designed to be soft and structuring, facilitating host tissue regeneration for volumetric soft tissue reconstruction.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

The large and growing global market for soft tissue reconstruction and augmentation, driven by aging populations and trauma cases, presents a significant opportunity.
A successful, durable, and minimally invasive regenerative product could displace temporary fillers and invasive surgical options, capturing substantial market share.
The platform nature of the technology allows for potential expansion into new tissue types and clinical indications.

Risk Factors

The company faces high technological and clinical risk as its novel biomaterial must prove safe and effective in human trials.
Regulatory pathways for such active scaffolds are complex and uncertain.
As a pre-revenue, private company, it is dependent on raising additional capital in a competitive funding environment to reach commercialization.

Competitive Landscape

Volumina competes in the broad soft tissue augmentation market against temporary and permanent dermal fillers (e.g., from Allergan, Galderma), autologous fat grafting techniques, and implant-based reconstruction. Its key differentiator is the aim to provide a minimally invasive, injectable, and *regenerative* solution that integrates with host tissue for durable volume restoration, a niche with few established players.

More companies in Regenerative Medicine →More companies in Switzerland →